High Cost Drugs a worldwide Issue Resolved in Mexico by the IMSS: Catalog II a Model to Follow

Morelos Adolfo García Sánchez1*, Ramón Armando Sánchez Tamayo1, Oswaldo Díaz González1, Mireya De La Fuente González2, Luis Andres Saenz Romero2, Elizabeth Mendoza Portillo2, María Isabel Estrada Rodríguez2, María De Los Ángeles Carmona Alva2, Imelda Yasmin Palma Cortés2, Daniel Pérez Nuñez2, Roxana Islas Mendoza2, Diego Enrique Martínez Castañeda5 and José Juan Lozano Nuevo6

1Medical Specialist, Coordinator of Medical Programs, Institutional Division of Basic Tables and Supplies for Health, Mexican Social Security Institute, National Autonomous University of Mexico, México City, Mexico
2General Surgeon, Surgical Department at “Dr. Gaudencio González Garza” General Hospital Specialized Medical Unit, “La Raza”, National Medical Center, Mexican Social Security Institute, National Autonomous University of Mexico, México City, México
3Internal Medicine and Critical Medicine Care, Intensive Care Unit Department at “Dr. Rubén Leñero” General Hospital Secretary of Health of Mexico City, National Autonomous University of Mexico, México City, Mexico
4Pediatrician, Pediatrician Department, Regional General Hospital No. 251, Metepec, Mexican Social Security Institute, National Autonomous University of Mexico, México State, México
5General Surgeon, Surgical Department at “Dr. Rubén Leñero” General Hospital Secretary of Health of Mexico City, National Autonomous University of Mexico, México City, México
6Internal Medicine, Internal Medicine Department at “Ticomán” General Hospital Secretary of Health of Mexico City, National Autonomous University of Mexico, México City, México

*Corresponding Author: Morelos Adolfo García Sánchez, Colonic and Rectal Surgeon and General Surgeon, Medical Specialist, Coordinator of Medical Programs, Institutional Division of Basic Tables and Supplies for Health, Mexican Social Security Institute, National Autonomous University of Mexico, México City, Mexico.

Received: June 24, 2021; Published: July 19, 2021

Historically, drugs are stigmatized in the history of medicine; where all civilization to date, makes use of superstition and the fable of diseases in their cure to divine causes. The great milestones of human history focuses on fighting disease and living longer in the best health conditions; that after centuries of efforts, successes and errors, medicine has experienced in recent decades an advance of such caliber that it has made it possible. The oldest form of pharmacology is documented in China Pentsao, attributed to the works ordered by Emperor Shemmeng 2,697 years BC. C. he codified more than 350 herbs that included medicinal plants like ginger, aconite, pomegranate root, rhubarb, opium, minerals like mercury, sulfur and arsenic [1]. The Ebers papyrus, 3,000 to 1,500 BC. C. describes a recipe mix for 700 substances, some in use today [2].

The elaboration of the medicines comes from the traditional extraction of active principles of medicinal plants, organic synthesis and the isolation of molecules with therapeutic effect. Towards the second half of the 20th century, industrial production takes off and the pharmaceutical sector experiences great development [3,4].

On the other hand, in Mexico, scientific and drug research activities are carried out with more bitterness in the Porfiriato (1876 - 1911), but already in 1917, companies dedicated to the production, importation and massive commercialization of drugs were established in our country. drugs, getting stronger until 1940; subsequently, European and US companies began to displace Mexican pharmaceutical

Citation: Morelos Adolfo García Sánchez, et al. "High Cost Drugs a worldwide Issue Resolved in Mexico by the IMSS: Catalog II a Model to Follow". EC Gastroenterology and Digestive System 8.8 (2021): 47-52.
companies. Achieving a dependency with the foreigner, thanks to the fact that the State with no interest and the few Mexican researchers with no support, they were never able to create a pharmaceutical industry in the national territory to this day [4].

Medicines are a fundamental pillar of public policies in any country in the world, their affordability is an economic trigger for the user with excessive cost, as well as for any public health financial system. With real problems such as research, development, availability, which together with the precariousness of health services, are faced with limitations in the supply and affordability of supplies and medicines. All of the above impacts even more and exponentially in the so-called high-cost drugs (MAC), adding the following characteristics:

- Diseases with a high impact of social repercussion.
- High risk of death.
- Very scarce population to be treated.
- Very high financial cost for the patient and the Health Institution.
- Governments must visualize financial viability, with scientific evidence and evaluating the budgetary impact [5].

The definition of MAC, in a certain percentage is immersed among them in a stigmatized linguistic effigy as orphan drugs (HM), these are for the treatment of rare diseases, called as low prevalence conditions with high chronically debilitating and incapacitating consequences or life threatening [6-9], in addition MAC in a greater proportion includes other diseases with very high cost treatments. To cite some examples are Crohn’s disease, Nonspecific Chronic Ulcerative Colitis, multiple sclerosis, colon and rectal cancer, lung cancer (others more oncological), rheumatological diseases, hematological diseases, etc.

There is a huge global problem that to date has not been resolved in relation to MACs, and puts in check the Governments, Secretaries or Ministries of Health, judicial systems, bonding companies, health insurance companies, group or labor insurance and the same patients; exposing themselves to a high degree of vulnerability [10,11]. The financial cost of MACs becomes the eye of the hurricane with regard to their accessibility and/or acquisition to the end user “the sick” [12,13]. That is why the objective of the following analysis of world problems.

The empires of power and influence of the pharmaceutical companies; whose objective is not clear and where, in addition, there is a certain lack of transparency, when determining the final cost of the drug, after its creation, production, distribution and/or marketing. They are also supported by patents and periods of exclusivity [7,14-17].

The so-called “missing links”, (failed and/or useless experimental, preclinical and clinical studies) carried out from 1975 to date, which consist of the research and development of drugs; that show a very high cost and therefore its increase in price [10,18,19].

The large economic impact of MAC makes it impossible to use them in diseases with high-cost doses, since in most of the public policies of nations around the world regarding health care; the inaccessibility of MACs results in legal requirements, which in the end exponentially triple the costs for the State [20,21].

The culture and influence of pharmaceutical empires on treating physicians, translates into an inclusive prescription making excessive use of MACs, which is defined as the provision of medical services that are more likely to harm than benefit a patient, or the considerable abuse of so-called polypharmacy [22,23].

The lack of research interest in verifying the effectiveness of MACs in the tropicalization of each country, with regard to their indication, prescription, complications, effectiveness, efficiency, their dosage and long-term follow-up, which in some Items may be greater
than 5 years, within the health systems applied around the world, it leaves an open door towards the optimization of the resource in rare
diseases, cancer and other high cost in their control and treatment [24,25].

Other factors that must be considered no less important are financial difficulties in terms of productivity of companies, distribution; in
the psychological responses of each patient, the administration and equity in the accessibility of the MAC, administrative procedures and
survival or survival to cancer, with the cost and continuity of an accumulated expense [26,27].

For all the above, it is imperative to find a solution to this global problem that MACs represent. In France the reimbursement of the cost
of the medicine is carried out by government decree issued in March 2016 by Haute Autorite, reporting catastrophic costs [28]. In Brazil,
the Specialized Program for Pharmaceutical Assistance is created to measure the cost and high prevalence drugs, but with very limited
coverage due to few patients and coverage for only some diseases [29]. On the other hand, the Department of Health and Human Services
of the United States of North America (USA) constantly scrutinizes the formula that responds to the exponential spending of MACs in that
country, such as reform, regular power or no, the prices through the Medicare program in its sections B and D, with a shared payment;
and that influences the international context [30-33]. In Europe (England, Switzerland, Germany and France) they develop strategic
negotiation scenarios to lower their prices, with research studies to achieve the health benefits in all countries of the use of MAC, for the
management of cancer [3,4].

In the region of Southeast Asia, in the Mediterranean region, the western and eastern Pacific, an inequity is detected in the price (unit
and adjusted) of MACs against cancer; proposing the development of policies and economics that achieve accessibility and affordability
[35]. In Canada, the allocation of health resources for the accessibility of MACs, as well as the creation of policies that may challenge phar-
maceutical companies, base their hope on a mosaic as diverse as group insurance, labor insurance, private insurers, etc. [11,27,36]. In
Australia there is a Pharmaceutical Benefits Program against cancer (PBAC), its functionality is to scrutinize MACs in the inclusion process
to grant the government subsidy; however, the rejection has been higher than 56%; and the most frequent reason for the rejection was
"the inadequate profitability or the price of the medicines too high" that is to say, it is not efficiently economical in a real life scenario in
this country [37].

In India for breast cancer they use generic MACs, achieving significant savings but not exceeding 25% of the total cost of the drug [38].
In other countries such as Portugal, Spain, France and Germany, the use of generics in rheumatological diseases is determined by comparing
them with the original drugs; the MACs (generic) used do not modify the efficacy, safety and immunogenicity profile, and if they work
they reduce costs by up to 26.4% [39-46].

Another strategy to reduce the costs of MACs that is identified is dose de-escalation that yields high savings, with a gradual decrease
in the dose for a successful and long-lasting effect [47,48].

Finally, in Mexico there is a logistics strategy that is an innovative, implausible, insurmountable, economically effective and efficient
program in the largest health institution in the country, the Mexican Institute of Social Security, which covers 70% of the population, al-
lowing not only the access of MACs, but also an affordability of innovative therapies to the population, managing to equate with a material
and human machinery, in the necessary treatment niches; with great equity, accessibility, efficiency, reasoned and specific prescription,
distribution, profitability, homogenization, rationalization, unification of criteria, without discrimination, with long-term sustainability;
And the best of all is that this administrative tool is translated into a potentializing link between health and life; in addition, it allows a gain
in quality and life expectancy of the patient: this strategy is called Catalog II [49].

There are two strategies that are mentioned with great impact so far:

Citation: Morelos Adolfo García Sánchez, et al. “High Cost Drugs a worldwide Issue Resolved in Mexico by the IMSS; Catalog II a Model
to Follow”. EC Gastroenterology and Digestive System 8.8 (2021): 47-52.
The first one is the model to follow: Catalog II of the IMSS in Mexico, which becomes the spearhead for the solution of the catastrophic global problem of MACs, and which becomes a part of the global waters; by reducing costs by demonstrating its effectiveness under specific scenarios in diseases with high-cost dosages.

The second is still speculation, where the authors project a certain viable future in the use of biotechnological and/or biosimilar therapies, as well as generic drugs; where it is seen as the tip of an iceberg, since it will be a future strategy that can solve a certain part of the global problem of MACs.

Bibliography


Citation: Morelos Adolfo García Sánchez, et al. “High Cost Drugs a worldwide Issue Resolved in Mexico by the IMSS; Catalog II a Model to Follow”. EC Gastroenterology and Digestive System 8.8 (2021): 47-52.


